文献速递细胞病理与分子病理

药物基因组学检测:临床实验室的策略与技术考量

Pharmacogenomic Testing: Strategies and Technical Considerations for Clinical Laboratories.
PubMed 文献 · Arch Pathol Lab Med · 2025-11-22

美国病理学家协会(CAP)工作组联合分子病理学协会和美国医学遗传学与基因组学学院,综述了临床实验室开展药物基因组学(PGx)检测的关键环节,包括检测平台、基因与变异选择、参考物质使用、星等位基因命名、基因型到表型转换及结果报告,并强调实验室应熟悉PGx基础、符合法规要求并遵循标准化命名与报告建议。

要点

  • PGx检测需考虑平台选择、基因与变异设计、参考物质及对照设置。
  • 应使用星等位基因和标准命名系统,并规范基因型到表型的转换。
  • 结果报告需包含用药建议,实验室对 vendor 报告工具负最终责任。

核心结论

  • 临床实验室应熟悉PGx基础,确保检测全过程符合法规要求,并遵循标准化命名和报告建议。

研究设计与样本

  • CAP成立由临床PGx检测专家组成的工作组,成员包括AMP和ACMG代表,工作组回顾相关文献、能力验证经验及成员实验室经验。

主要发现

  • 工作组推荐实验室实施PGx检测时考虑检测平台、检测设计(药物基因和变异/等位基因选择)、参考物质在开发及临床运行中的使用、星等位基因和标准命名系统、基因型到预测表型的转换以及结果报告(包括用药建议)。
  • 工作组还提供了使用报告供应商时的考量,强调临床实验室在采用供应商报告工具时的角色和责任。

临床怎么用

  • 实验室开展PGx检测应参考工作组推荐,关注平台、设计、对照、命名、表型转换和报告等关键环节。
  • 使用 vendor 报告工具时,临床实验室应明确自身责任并确保符合法规要求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: Clinical laboratories are increasingly implementing pharmacogenomic (PGx) testing. Although PGx is similar to genetic testing for other indications, there are unique aspects that laboratories should consider. OBJECTIVE.—: To aid clinical laboratories that are implementing clinical PGx testing by describing characteristics of PGx test design and validation, as well as approaches to reporting. Resources that are useful for clinical laboratories performing PGx testing will be highlighted. DESIGN.—: The College of American Pathologists formed a workgroup composed of laboratorians with expertise in clinical PGx testing. The workgroup included representatives from the Association for Molecular Pathology and the American College of Medical Genetics and Genomics. The workgroup reviewed pertinent literature, as well as experience from proficiency testing and from members' laboratories. RESULTS.—: The workgroup recommends that laboratories implementing PGx consider the following concepts: testing platform, test design (ie, selection of pharmacogenes and variants/alleles), use of reference materials during test development and as controls during clinical runs, star allele and standard nomenclature systems, translations from genotype to predicted phenotype, and considerations for result reporting including making medication recommendations. The workgroup provides considerations when using report vendors, emphasizing the clinical laboratory's role and responsibility when implementing such reporting tools from vendors. CONCLUSIONS.—: Clinical laboratories should be familiar with the fundamentals of PGx, ensure that PGx testing meets the applicable regulatory requirements for all aspects of the clinical laboratory testing process, and follow recommendations for standardization of nomenclature and reporting.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Ji Y, Brunk L, Bove B, et al. Pharmacogenomic Testing: Strategies and Technical Considerations for Clinical Laboratories. Arch Pathol Lab Med. 2025. PMID: 41270809. doi:10.5858/arpa.2025-0179-CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。